Renal Denervation: A Revival or The Same Old Story

Forouzanfar, 2015, Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study2013, Lancet, 386, 2287, 10.1016/S0140-6736(15)00128-2 Mills, 2016, Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 Countries, Circulation, 134, 441, 10.1161/CIRCULATIONAHA.115.018912 Hird, 2019, Productivity burden of hypertension in Australia, Hypertension, 73, 777, 10.1161/HYPERTENSIONAHA.118.12606 Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939 Chobanian, 2003, Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2 Daugherty, 2012, Incidence and prognosis of resistant hypertension in hypertensive patients, Circulation, 125, 1635, 10.1161/CIRCULATIONAHA.111.068064 Yang, 2017, Antihypertensive medication adherence and risk of cardiovascular disease among older adults: a population-based cohort study, J Am Heart Assoc, 6, e006056, 10.1161/JAHA.117.006056 Katholi, 2009, The role of renal sympathetic nerves in hypertension: has percutaneous renal denervation refocused attention on their clinical significance?, Prog Cardiovasc Dis, 52, 243, 10.1016/j.pcad.2009.09.003 Esler, 1988, Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover, Hypertension, 11, 3, 10.1161/01.HYP.11.1.3 Schultz, 2007, Arterial chemoreceptors and sympathetic nerve activity: implications for hypertension and heart failure, Hypertension, 50, 6, 10.1161/HYPERTENSIONAHA.106.076083 Stella, 1991, Functional role of renal afferents, Physiol Rev, 71, 659, 10.1152/physrev.1991.71.3.659 Schiller, 2013, Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure, Am J Physiol Regul Integr Comp Physiol, 305, R886, 10.1152/ajpregu.00269.2013 Smithwick, 1953, Splanchnicectomy for essential hypertension: results in 1,266 cases, J Am Med Assoc, 152, 1501 Krum, 2009, Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study, Lancet, 373, 1275, 10.1016/S0140-6736(09)60566-3 2011, Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months, Hypertension, 57, 911, 10.1161/HYPERTENSIONAHA.110.163014 Krum, 2014, Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study, Lancet, 383, 622, 10.1016/S0140-6736(13)62192-3 2010, Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial, Lancet, 376, 1903, 10.1016/S0140-6736(10)62039-9 Esler, 2014, Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial, Eur Heart J, 35, 1752, 10.1093/eurheartj/ehu209 Kandzari, 2012, Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 trial, Clin Cardiol, 35, 528, 10.1002/clc.22008 Kandzari, 2015, Predictors of blood pressure response in the SYMPLICITY HTN-3 trial, Eur Heart J, 36, 219, 10.1093/eurheartj/ehu441 Kandzari, 2016, The SPYRAL HTN global clinical trial program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications, Am Heart J, 171, 82, 10.1016/j.ahj.2015.08.021 Osborn, 2018, Catheter-based renal nerve ablation as a novel hypertension therapy: lost, and then found, in translation, Hypertension, 71, 383, 10.1161/HYPERTENSIONAHA.117.08928 Böhm, 2020, Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial, Lancet, 395, 1444, 10.1016/S0140-6736(20)30554-7 Mahfoud, 2015, Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design, Eur Heart J, 36, 2219, 10.1093/eurheartj/ehv192 Kandzari, 2018, Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial, Lancet, 391, 2346, 10.1016/S0140-6736(18)30951-6 Böhm, 2019, TCT-84 renal denervation with Symplicity Spyral catheter in the Global Symplicity Registry: safety and efficacy at 3 years, J Am Coll Cardiol, 74, B84, 10.1016/j.jacc.2019.08.124